Skip to content
← Back to this collection

PUBLICATIONS · 20807892

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2010 Dec 2
First author
Bringhen S

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2012 Dec 20;120(26):5250
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Blood. 2010 Dec 2;116(23):4733-4. doi: 10.1182/blood-2010-10-306373.
    note
    Source null
    related pmid
    21127178
    relationship
    Comment in

Authors and identifiers

  1. name
    Bringhen S
    type
    Author
  2. name
    Larocca A
    type
    Author
  3. name
    Rossi D
    type
    Author
  4. name
    Cavalli M
    type
    Author
  5. name
    Genuardi M
    type
    Author
  6. name
    Ria R
    type
    Author
  7. name
    Gentili S
    type
    Author
  8. name
    Patriarca F
    type
    Author
  9. name
    Nozzoli C
    type
    Author
  10. name
    Levi A
    type
    Author
  11. name
    Guglielmelli T
    type
    Author
  12. name
    Benevolo G
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bringhen S
    type
    Author
  2. name
    Larocca A
    type
    Author
  3. name
    Rossi D
    type
    Author
  4. name
    Cavalli M
    type
    Author
  5. name
    Genuardi M
    type
    Author
  6. name
    Ria R
    type
    Author
  7. name
    Gentili S
    type
    Author
  8. name
    Patriarca F
    type
    Author
  9. name
    Nozzoli C
    type
    Author
  10. name
    Levi A
    type
    Author
  11. name
    Guglielmelli T
    type
    Author
  12. name
    Benevolo G
    type
    Author
bibliography ids
  1. nci-bib-6700ce307f9724c01fb4364a
book metadata
content sha256
fc22f31c428f2c1c1dac6e19a7f0815760bf087de7f534f0fcbbb10e7afc13fa
document type
citation
dois
  1. 10.1182/blood-2010-07-294983
electronic publication date
display
2010 Aug 31
precision
day
year
2010
evidence scope
bibliographic_metadata_only
id
pubmed:20807892
immutable id
pubmed:20807892@fc22f31c428f2c1c1dac6e19a7f0815760bf087de7f534f0fcbbb10e7afc13fa
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
23
name
Blood
nlm unique id
7603509
pages
4745-53
volume
116
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2012 Dec 20;120(26):5250
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Blood. 2010 Dec 2;116(23):4733-4. doi: 10.1182/blood-2010-10-306373.
    note
    Source null
    related pmid
    21127178
    relationship
    Comment in
outcomes validated
false
pmid
20807892
provenance
batch id
10a38257e12e9ed1867a
provider
NCBI PubMed ESummary
record sha256
612d4c27300dfcb29157da4487774f7843b3c2f9b68b2553a24a4bbab91aa873
response sha256
84c4808ca38b35d999cfdf809eb088835175ab38d71586c626096d677096bbcc
retrieved at
2026-09-09T23:46:35.793530+00:00
publication date
display
2010 Dec 2
precision
day
year
2010
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/20807892/
title
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Preserved source evidence · Not medical advice